Using a protein test to measure inflammation in IBD
Part of Digestive system clinical trials.
This study looks at a protein called claudin 2 in tissue samples from people with inflammatory bowel disease (IBD). The goal is to see if it can help doctors tell whether inflammation is active or inactive. This could lead to a more accurate way to check disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of inflammatory bowel disease (IBD)
- You have had a colonoscopy with tissue samples (biopsies) taken
- You have not had a diagnosis of IBD that is uncertain or unconfirmed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests non-invasive tools to find active inflammation in people with Crohn's disease or ulcerative colitis. You may need to give extra stool samples before your colonoscopy and calprotectin test.
This study looks at whether certain blood tests (called inflammatory biomarkers) can help measure how active your inflammatory bowel disease (Crohn's disease or ulcerative colitis) is. It may help doctors better track your condition and guide treatment, without needing invasive procedures.
This study measures a blood protein called LRG and compares it to how active your inflammatory bowel disease (IBD) is during a planned scope procedure. The goal is to see if this blood test could help doctors assess disease activity more easily in the future.
This study looks at how your blood tests (inflammation levels) change after you start or adjust your treatment for ulcerative colitis or Crohn's disease. It also checks how your gut heals by looking at tissue samples from a follow-up colonoscopy.
This study collects blood, stool, tissue, and health information from people with inflammatory bowel disease (IBD), their relatives, and healthy volunteers to find patterns that may help diagnose or treat IBD better in the future.
This study looks for “biomarkers” (lab markers, like substances in blood or tissue) that may predict how Crohn’s disease or ulcerative colitis will go and how patients may respond. It may help doctors choose better monitoring or treatments in the future.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.